熱門資訊> 正文
Zentalis Pharmaceuticals GAAP每股收益为-1.24美元
2024-08-09 22:09
- Zentalis Pharmaceuticals press release (NASDAQ:ZNTL): Q2 GAAP EPS of -$1.24.
- Cash, Cash Equivalents and Marketable Securities Position: As of June 30, 2024, Zentalis had cash, cash equivalents and marketable securities of $426.4 million,
-
More on Zentalis Pharmaceuticals
- Zentalis faces partial FDA hold on lead asset; Wedbush downgrades (update)
- Seeking Alpha’s Quant Rating on Zentalis Pharmaceuticals
- Historical earnings data for Zentalis Pharmaceuticals
- Financial information for Zentalis Pharmaceuticals
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。